No connection

Search Results

MDAI

BEARISH
$1.85 Live
Spectral AI, Inc. · NASDAQ
Target $4.67 (+152.3%)
$1.13 52W Range $3.21

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 14, 2026
Market cap
$58.87M
P/E
N/A
ROE
N/A
Profit margin
-38.5%
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
MDAI exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental strength across all measured categories. The company suffers from severe revenue contraction (-46.30% YoY) and a negative Price-to-Book ratio (-9.89), which suggests negative shareholder equity and potential insolvency. While analysts maintain a 'strong_buy' rating with a target of $4.67, this is fundamentally disconnected from the current balance sheet and operational decay. The stock is currently a high-risk speculative vehicle rather than a value investment.

Key Strengths

Positive gross margin of 45.42%
Recent short-term price momentum (+40.1% in 1 month)
Positive Q/Q EPS growth from a very low base
Strong analyst price targets relative to current price
Operating in the high-growth Medical Devices sector

Key Risks

Extreme financial fragility (Piotroski 0/9)
Negative equity as indicated by Price/Book of -9.89
Severe revenue collapse (-46.30% YoY)
Liquidity risk with a Current Ratio below 1.0 (0.94)
High cash burn with operating margins at -54.90%

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
10
Weak
Value
10
Future
20
Past
20
Health
0
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Catastrophic Piotroski score, Negative equity, Collapsing revenue growth, Liquidity shortfall
Confidence
90%
Value
10/100

Graham Number and Intrinsic Value are unavailable due to negative earnings and equity.

Positives
No standout positives identified.
Watchpoints
  • Negative Price/Book ratio
  • P/S of 3.00 is expensive for a company with shrinking revenue
Future
20/100

Growth metrics are trending sharply downward.

Positives
  • Analyst optimism
Watchpoints
  • Revenue growth is -46.30% YoY
  • Q/Q revenue growth is -46.27%
Past
20/100

Long-term performance is overwhelmingly negative.

Positives
  • 1Y price return of +48%
Watchpoints
  • 5Y change of -81.1%
  • Consistent history of earnings misses
Health
0/100

The company fails every deterministic health check.

Positives
No standout positives identified.
Watchpoints
  • Piotroski F-Score 0/9
  • Current Ratio < 1.0
  • Negative ROA
Dividend
0/100

Dividend strength is 0/100.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No capacity for dividends

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$1.85
Analyst Target
$4.67
Upside/Downside
+152.3%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for MDAI and closest competitors.

Updated 2026-04-13
MDA
Spectral AI, Inc.
Primary
5Y
-81.1%
3Y
-87.0%
1Y
+48.0%
6M
-16.3%
1M
+40.1%
1W
+11.4%
LUN
Pulmonx Corporation
Peer
5Y
-96.7%
3Y
-86.8%
1Y
-73.4%
6M
-9.4%
1M
-14.3%
1W
+5.9%
DCG
DocGo Inc.
Peer
5Y
-94.3%
3Y
-93.1%
1Y
-77.6%
6M
-55.1%
1M
-15.2%
1W
-9.4%
BTM
biote Corp.
Peer
5Y
-85.2%
3Y
-74.7%
1Y
-54.1%
6M
-47.5%
1M
-16.8%
1W
+10.4%
ICC
ImmuCell Corporation
Peer
5Y
-21.2%
3Y
+44.8%
1Y
+39.6%
6M
+4.1%
1M
+6.5%
1W
+9.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-2.15
PEG Ratio
N/A
P/B Ratio
-9.89
P/S Ratio
3.0
EV/Revenue
2.74
EV/EBITDA
-6.32
Market Cap
$58.87M

Profitability

Profit margins and return metrics

Profit Margin -38.53%
Operating Margin -54.9%
Gross Margin 45.42%
ROE N/A
ROA -32.1%

Growth

Revenue and earnings growth rates

Revenue Growth -46.3%
Earnings Growth N/A
Q/Q Revenue Growth -46.27%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
0.94
Weak
Quick Ratio
0.81
Poor
Cash/Share
$0.48

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
45.2%
Op. Margin
-54.9%
Net Margin
25.7%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$-0.0B
Debt/Equity
-4.74x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-12
$N/A
2026-03-25
$0.02
+114.3% surprise
2025-11-11
$-0.13
-52.9% surprise
2025-08-12
$-0.31
-287.5% surprise

Healthcare Sector Comparison

Comparing MDAI against 319 companies in the Healthcare sector (20 bullish, 107 neutral, 192 bearish)
Profit Margin
-38.53%
This Stock
vs
-11.76%
Sector Avg
+227.7% (Superior)
Revenue Growth
-46.3%
This Stock
vs
90.15%
Sector Avg
-151.4% (Slower)
Current Ratio
0.94
This Stock
vs
3.67
Sector Avg
-74.3% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

CAPONE VINCENT S
Chief Executive Officer
Stock Award
2026-03-27
16,750 shares · $25,460
DIMAIO JOHN MICHAEL
Director
Stock Award
2026-03-27
7,619 shares · $12,038
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
STRONG_BUY
3 analysts
BTIG
2026-03-25
reit
Buy Buy
BTIG
2026-02-10
reit
Buy Buy
BTIG
2025-11-12
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning MDAI from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile